GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-07644-6
Abstract: Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific… read more here.
Keywords: vivo growth; dependent tumors; mutant kras; kras dependent ... See more keywords
Abstract PR09: KRAS-targeted PROTAC degraders are broadly efficacious against KRAS-dependent tumor models
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-pr09
Abstract: KRAS is genomically altered in about one third of all human tumors. Due to its central role in oncogenesis, many attempts have been made in the last four decades to drug mutant KRAS, either directly… read more here.
Keywords: kras dependent; targeted protac; mutant kras; kras targeted ... See more keywords